Mobile Menu

May pharma-published AI and Real World Evidence articles

Benjamin Hughes, Senior Vice President of Artificial Intelligence and Real World Data at IQVIA, has again collated the leading AI and RWD-focused articles published this month across the journals. Here, we take a look at the pharma-published entries, some on COVID-19.

Various pharma – combine with FWD, NIH and EMA, to publish their FAIR principles and the need for Common Data Elements (CDEs) in their implementation

FAIR data sharing: The roles of common data elements and harmonization

Pfizer – looks at the role of RWE in oncology approvals during the period 2016-19

Role of real-world evidence for oncology product registration in the United States: A review of approvals by the U.S. Food and Drug Administration from 2015 to 2019.

Pfizer/Sanofi – highlight the importance of machine learning in health economics and outcomes research, to identify clinically relevant sub-groups

Machine Learning for Precision Health Economics and Outcomes Research (P-HEOR): Conceptual Review of Applications and Next Steps

Janssen/OHDSI – also with IQVIA authors, they published a systematic review of first line anti-hypertensives using RWD from five million patients across five countries

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis

Roche – speculate that COVID-19 will accelerate the use of RWE in access and evidence/data-based decision-making

Life after COVID-19: R WE going to help?

Janssen – using Columbia observational medical outcomes partnership (OMOP) data and four trial comparisons, suggest that trial eligibility criteria are so different to real-world populations that they cannot be used alone for label/licensing

Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations

AstraZeneca – levers the fusion database linked to SHA claims to profile healthcare utilisation of 20,000 patients on LAMA/LABA fixed dose combinations

Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice

AstraZeneca – uses the IQVIA PMX+ database to profile treatment patterns for younger patients with chronic lymphocytic leukaemia

Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients With Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study

Merck – uses the German IGef claims database to profile 500 patients with multiple sclerosis, high HDA  especially within the young RRMS population

Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data

GSK – lever IQVIA UK IMRD (EMR) to suggest higher persistence and adherence to ICS/LABA in asthma across 5,000 patients

Persistence and Adherence to ICS/LABA Drugs in UK Patients With Asthma: A Retrospective New-User Cohort Study

GSK – on ICS/LABA/LAMA combination in Japan, levering the JMDC claims database to profile overall utilisation patterns

Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan

Boehringer Ingelheim – sponsor a study using Japanese MDV claims to profile bleeding incident rates of NOAC patients undergoing surgery

Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy

Pfizer – lever Optum EMR to determine stroke rates from patients undergoing elective lumbar fusion

The incidence of stroke among selected patients undergoing elective posterior lumbar fusion: a retrospective cohort study

Roche/Genentech – lever McKesson U.S. oncology network to examine patient outcomes with HER2+ breast cancer, with the pathological response (pCR) after nPT and adjuvant trastuzumab (aT)

Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence

Source article: Benjamin Hughes on LinkedIn

More on these topics

AI / Real World Data / Real World Evidence

Share this article